Cardiol Therapeutics, Inc. (CRDL) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.06

From 52W high−55.90%

Volume869731.00

Market cap$122.73M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.06

From 52W high

−55.90%

Volume

869731.00

Market cap

$122.73M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.0x

P/E (TTM)

—

RSI (14)

24.9

MomentumView details →

1D Return

−3.81%

YTD Return

+5.37%

SummaryUpdated Jun 1, 2026

Cardiol Therapeutics Inc. (NASDAQ:CRDL) is a clinical-stage Canadian biopharmaceutical company founded in 2017 and headquartered in Oakville, Ontario. The company went public in January 2019 and focuses on developing innovative therapies to treat cardiovascular diseases through anti-fibrotic and anti-inflammatory approaches. As a clinical-stage company, Cardiol has no commercial products yet and is currently conducting Phase II/III trials for its lead drug candidate, CardiolRx, targeting heart-related conditions including COVID-19 cardiovascular complications and acute myocarditis.

Ask drillr about Cardiol Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

7.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−152.53%

ROA (TTM)

−124.84%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+27.48%

FCF YoY

+3.88%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+23.53%

EBITDA YoY

−1.88%

MomentumView details →

1D Return

−3.81%

YTD Return

+5.37%

1Y Return

−7.80%

RSI (14)

24.9

vs 50D SMA

−35.98%

vs 200D SMA

−22.92%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.55x

Quick Ratio

5.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.04

EPS Surprise

55.56%

Beats (12Q)

9/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

19.44%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−36.67M

Op. CF (TTM)

−24.07M

Next earningsNov 12, 2026 →

Latest newsMore news →

Cardiol Therapeutics entered into a sales agreement with JEFFERIES LLC for an at-the-market program to offer and sell up to US$75 million of its common shares.1d ago

Cardiol Therapeutics achieved its Phase III MAVERIC enrollment target of 110 patients ahead of schedule and expanded the pivotal trial of CardiolRx™ to up to 150 patients.43d ago

Similar companies

BGM Group Ltd.BGM Huakang Biomedical Holdings Company Limited08622.HK Journey Medical CorporationDERM Organogenesis Holdings Inc.ORGO Organigram Global Inc.OGI Extrawell Pharmaceutical Holdings Limited00858.HK Find similar companies →

Latest newsMore news →

Cardiol Therapeutics entered into a sales agreement with JEFFERIES LLC for an at-the-market program to offer and sell up to US$75 million of its common shares.1d ago Cardiol Therapeutics achieved its Phase III MAVERIC enrollment target of 110 patients ahead of schedule and expanded the pivotal trial of CardiolRx™ to up to 150 patients.43d ago